Inspiremd announces approval of investigational device exemption (ide) application for cguardians ii pivotal study of the cguard prime 80cm carotid stent system

Miami, oct. 07, 2024 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced that the u.s. food and drug administration (fda) has approved the company's investigational device exemption (ide) application to initiate the cguardians ii pivotal study of its cguard prime 80cm carotid stent system during transcarotid revascularization (tcar) procedures.
NSPR Ratings Summary
NSPR Quant Ranking